Abivax to Present Data on Obefazimod at Digestive Disease Week® Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST – (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immun...
GTT: Q1 2026 Activity Update - Press Release Strong commercial momentum in the first quarter of 2026;Revenues of 193 million euros, in line with expectations Strong commercial momentum: In the first quarter of 2026, 32 orders recorded compared with 16 in the first quarter of 2025Revenues of 193 million euros, up 1% compared with the first quarter of 2025To date, the Middle East conflict has no direct impact on GTT’s business activity; 2026 objectives confirmed Paris, April 22, 2026. GTT, the technological expert in membrane containment systems used to transport and store liquefied gases,...
GTT: Activité du 1er trimestre 2026 - Communiqué de Presse Forte dynamique commerciale au premier trimestre 2026 ;Chiffre d’affaires de 193 M€ conforme aux attentes Forte dynamique commerciale : 32 commandes enregistrées au premier trimestre 2026 vs 16 au premier trimestre 2025Chiffre d’affaires de 193 millions d’euros, en hausse de 1% par rapport au premier trimestre 2025 A date le conflit au Moyen-Orient n’a pas d’impact direct sur l’activité de GTT ; objectifs 2026 confirmés Paris – Le 22 avril 2026. GTT, l'expert technologique des systèmes de confinement à membranes dédiés au transpo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.